Findings suggest significant reduction in the risk of CV death and all-cause mortality for T2DM patients with a history of CVD.

Your patient has been taking metformin, glipizide and a daily basal insulin dose (.85 U/kg/day). While his fasting glucose levels are on target, he have not yet been able to reach his individualized glycemic target of A1C<7%. In your discussion with him about the addition of a prandial insulin dose to his regimen, you compare and contrast his options. Compared to basal insulin alone, premixed insulins: Follow link to give your answer!

Studies have shown that 40-80 percent of the medical information patients receive is forgotten immediately and nearly half of the information retained is incorrect. One of the easiest ways to close the gap of communication between clinician and patient is to employ the “teach-back” method, also known as the “show-me” …

We’re excited to let you know that on October 1st, 2015, we will be relaunching DiabetesInControl.com. The refreshed site will feature a clean, new look and feel, with enhanced navigation to make it even easier to find all our great content. We’ve also decided to make some of our most …

Reminder – on October 1st, 2015, we will be relaunching DiabetesInControl.com. The refreshed site will feature a clean, new look and feel, with enhanced navigation to make it even easier to find all our great content. We’ve also decided to make some of our most popular content, including our “Tools …

Patient, female, 54 years of age, type 2 diabetes and obesity, told me she thought her weight and subsequent type 2 diabetes related to overeating, especially large portions. She is being seen by a behavior therapist for her eating disorder. I started her on a GLP-1. Even at starting dose, she reported feeling more satiated, but still overeating. The dose was increased...

Tool for Your Practice (Subscribers Only)

It seems like every time we get good news about a diabetes drug, the bad has to surface. This week, Lilly and BI announced some great heart results with their drug Jardiance, while the FDA tightened up its warning on Invokana and fracture risk. The same thing happens in other …

Tool for Your Practice (Subscribers Only)

Product of the Week - connected digital health prototype enables people living with diabetes and their health care providers to make more confident care decisions, while managing the complexity of diabetes self-care.